Israel - English - Ministry of Health

unipharm ltd, israel - tinidazole - tablets - tinidazole 500 mg - tinidazole - for the oral treatment of trichomonas vaginals infections of the genito urinary tract in both female and male. for the prevention of anerobic infections after gynocological operations and stomach operations.

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 10 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels. pravastatin is indicated to: 1) reduce the risk of recurrent myocardial infarction. 2)reduce the risk of undergoing myocardial revascularization procedures. 3) reduce the risk of stroke or transient ischemic attack (tia). c) hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (frederickson type iia and iib).

Israel - English - Ministry of Health

unipharm ltd, israel - amisulpride - film coated tablets - amisulpride 100 mg - amisulpride - treatment of schizophrenia.

Israel - English - Ministry of Health

unipharm ltd, israel - amisulpride - film coated tablets - amisulpride 400 mg - amisulpride - treatment of schizophrenia.

Israel - English - Ministry of Health

unipharm ltd, israel - risedronic acid as sodium - tablets - risedronic acid as sodium 150 mg - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previ

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous my

Israel - English - Ministry of Health

unipharm ltd, israel - atomoxetine as hydrochloride - coated tablets - atomoxetine as hydrochloride 25 mg - atomoxetine - atomic is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. treatment must be initiated by a specialist in the treatment of adhd, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. diagnosis should be made according to current dsm criteria or the guidelines in icd. in adults, the presence of symptoms of adhd that were pre-existing in childhood should be confirmed. third-party corroboration is desirable and atomic should not be initiated when the verification of childhood adhd symptoms is uncertain. diagnosis cannot be made solely on the presence of one or more symptoms of adhd.based on clinical judgment, patients should have adhd of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.